

BOSTON SCIENTIFIC ANNOUNCES SCHEDULE FOR EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS

Natick, MA (August 27, 2009) -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements for the European Society of Cardiology (ESC) Congress, which runs from August 29 to September 2 in Barcelona. Highlights include final results from the MADIT-CRT trial and two-year results from the SYNTAX trial.

"Boston Scientific is proud to be the exclusive sponsor of the landmark MADIT-CRT trial, and we look forward to the presentation of the final data at ESC," said Ray Elliott, President and Chief Executive Officer of Boston Scientific. "MADIT-CRT is breaking new ground by demonstrating that early intervention with cardiac resynchronization defibrillation therapy (CRT-D) slows the progression of heart failure when compared to standard implantable cardioverter defibrillator (ICD) therapy. We are also looking forward to the presentation of two-year data from our SYNTAX trial, comparing the use of percutaneous coronary intervention (PCI) using the TAXUS[®] Express²[®] Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery in patients with complex disease. We are hopeful these results will build on the one-year data, which showed comparable safety outcomes for PCI and CABG."

Details of the Company's activities at ESC are below.

Schedule of Events (All times are local Barcelona; all events are held at the Fira Gran Via Convention Center.)

Sunday, August 30

- **HORIZONS-AMI Trial Results.** One-year data from the HORIZONS-AMI trial will be presented in a poster session at 8:30 a.m. The trial was designed to determine the safety and efficacy of the TAXUS Express² Paclitaxel-Eluting Coronary Stent System compared to bare-metal stenting in patients experiencing an acute myocardial infarction (AMI). Results will focus on the relative impact of ischemic complications and varying definitions of major bleeding on one-year mortality in patients with AMI.

Monday, August 31

- **Clinical Seminar - The SYNTAX Trial: One Year On.** The Company will sponsor a clinical seminar chaired by Miguel Sousa Uva, M.D., and Antonio Colombo, M.D., from 4:30-6:00 p.m. in the Madrid Room. Discussion topics will include the view of the non-interventional cardiologist and conclusions from subgroup analyses.

Tuesday, September 1

- **MADIT-CRT Trial Data.** Final results from the MADIT-CRT trial will be presented by Arthur Moss, M.D., during a Hot Line presentation session at 12:15 p.m. in the Barcelona Room. The MADIT-CRT trial has more than 1,800 patients and examines whether early intervention with cardiac resynchronization therapy in high-risk, New York Heart Association Class I and II patients slows the progression of heart failure when compared to implantable cardioverter defibrillator (ICD) therapy. The Company plans to issue a press release simultaneous with an ESC press conference, which begins at 8:00 a.m.
- **Analyst Conference Call.** The Company will webcast a conference call beginning at 2:00 p.m. to discuss final results from the MADIT-CRT trial. The live webcast and archived replay of this call will be available at www.bostonscientific.com in the Investor Relations section. The webcast is also being distributed over Thomson Financial's Investor Distribution Network via two locations: www.earnings.com, which is accessible to the public, and www.streetevents.com, a password-protected event management site.
- **PreSCD II Registry Data.** Final results of the PreSCD II registry will be presented by Heinz Voeller, M.D., during a Hot Line presentation session at 12:00 p.m. in the Barcelona Room. The PreSCD registry has enrolled 10,000 post-myocardial infarction patients in 19 centers in Germany with follow-up to 36 months. The study was designed to identify patients at risk of sudden cardiac death and to evaluate the use of ICD therapy. The Company plans to issue a press release at this time.
- **Lunch Workshop - Device Therapy in Treating Heart Failure.** The Company will sponsor a lunch workshop from 12:45-1:30 p.m. in the Belgrade Room titled "The ever growing role of device therapy in the treatment of heart failure," chaired by Dr. Moss and Pedro Brugada Terradellas, M.D. The workshop will explore new approaches to managing the progression of heart failure and the role of remote patient management.
- **Satellite Symposium - Tackling Complex Coronary Disease.** The Company will sponsor a satellite symposium titled "Tackling complex coronary disease anno 2009: scientific and technological progress," chaired by Stephan Windecker, M.D., and Keith Dawkins, M.D., from 2:00-3:30 p.m. in the Belgrade Room. Discussion topics will include the evolution of drug-eluting stents, the promise of new stent technology and case a study with a new stent platform. Boston Scientific's new Element™ Stent platform will be featured, along with other new technologies.

Wednesday, September 2

- **SYNTAX Study Update.** Two-year outcomes data from the SYNTAX trial will be presented by A. Pieter Kappetein, M.D., at 9:15 a.m. during a Clinical Trial Update session in the Barcelona Room. SYNTAX is the first randomized, controlled clinical trial comparing PCI using drug-eluting stents to CABG surgery in patients with left main and/or three-vessel disease. The Company plans to issue a press release at this time.

Boston Scientific will present its latest innovations at booth C99 in the Exhibition Hall. Cardiovascular and cardiac rhythm management products will include the LATITUDE[®] Patient Management System, which was recently launched in Europe, and the Company's third-generation drug-eluting stents: the TAXUS[®] Element[™] Paclitaxel-Eluting Coronary Stent System and the PROMUS[®] Element[™] Everolimus-Eluting Coronary Stent System.

The Company is still expecting CE Mark approval and launch for both the TAXUS Element and the PROMUS Element Stent Systems in the fourth quarter of this year. The TAXUS Element and PROMUS Element Stent Systems are not available for sale in the United States.

The safety and effectiveness of the TAXUS[®] Express[®] Stent has not been established in patients with left main or three-vessel disease.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA- *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that

actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation

Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific Corporation